Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301713 | 1.00 | CNR2 (0.52) | CNR2RAB9AL3MBTL1KDM4ESTAT3 | |
| SCHEMBL4122649 | 0.82 | KMT2A (0.58) | CNR2RAB9AL3MBTL1KDM4ECYP2A6 | |
| SCHEMBL16291327 | 0.82 | RAB9A (0.52) | CNR2RAB9AL3MBTL1KDM4ECYP2A6 | |
| SCHEMBL16291275 | 0.82 | CNR2 (0.49) | CNR2RAB9ACYP2A6HDAC3HDAC4 | |
| SCHEMBL16291405 | 0.82 | TDP1 (0.50) | CNR2RAB9AL3MBTL1NPC1TP53 | |
| Hydrochloric Acid SCHEMBL3062533 | 0.81 | KMT2A (0.57) | CNR2RAB9AL3MBTL1KDM4ENPC1 | |
| SCHEMBL10636707 | 0.81 | CNR2 (0.48) | CNR2RAB9AKDM4ECYP2A6HDAC3 | |
| SCHEMBL349832 | 0.80 | CNR2 (0.56) | CNR2RAB9ACYP2A6HDAC3HDAC4 | |
| SCHEMBL27799255 | 0.80 | CNR2 (0.47) | CNR2RAB9ACYP2A6HDAC3HDAC4 | |
| SCHEMBL4404077 | 0.80 | CNR2 (0.64) | CNR2RAB9ACYP2A6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444430-A | Off-on near infrared lead ion detection fluorescent probe YSQ and preparation method and application thereof | 江苏科技大学 | 2023-07-18 | — | — | CN | claimed |
| CN-113637004-B | Aluminum ion detection fluorescent probe based on bifunctional small organic molecule as matrix, and preparation method and application thereof | 江苏科技大学 | 2022-09-23 | — | — | CN | claimed |
| CN-114790200-A | Fluorescence-enhanced zinc ion detection fluorescent probe ENO and preparation method and application thereof | 江苏科技大学 | 2022-07-26 | — | — | CN | claimed |
| CN-110590756-B | Phenolphthalein Schiff base fluorescent probe and preparation method and application thereof | 南通大学 | 2022-04-22 | — | — | CN | claimed |
| CN-113637004-A | Aluminum ion detection fluorescent probe based on dual-functional organic micromolecule as matrix and preparation method and application thereof | 江苏科技大学 | 2021-11-12 | — | — | CN | claimed |
| CN-110590756-A | Phenolphthalein Schiff base fluorescent probe and preparation method and application thereof | 南通大学 | 2019-12-20 | — | — | CN | claimed |
| CN-104447547-B | Synthesis method of 4-aminoisoquinoline-8-methyl formate | 苏州康润医药有限公司 | 2017-04-19 | — | — | CN | claimed |
| EP-4724430-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | Flagship Pioneering Innovations VI, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| WO-2024254396-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-118955323-A | Used for Al3+Naphthalene schiff base fluorescent probe for detection, preparation method and application | 西安石油大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-117286192-B | Use of amide synthetases in the preparation of litaxetil intermediates and/or litaxetil | 欣雅利华生物技术(上海)有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117286192-A | Use of amide synthetases in the preparation of litaxetil intermediates and/or litaxetil | 欣雅利华生物技术(上海)有限公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-0934920-A2 | Preparation of hydrogenated compounds using noble metal Raney catalysts | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5631264-A | NEUROLOGICAL DISORDERS | SANOFI WINTHROP, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0724908-A1 | Noble metal raney catalysts and preparation of hydrogenated compounds using such catalysts | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1996-08-07 | — | — | EP | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0030198-B1 | ISOQUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC SANTE (FR) | 1983-03-02 | — | — | EP | disclosed |
| EP-0030198-A1 | Isoquinoline derivatives, their preparation and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | CNR2 1818/4885RAB9A 1984/4885L3MBTL1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.